We can’t show the full text here under this license.
Differences by race and demographics in using GLP-1 receptor agonists among breast cancer patients with Type 2 diabetes
Updated
Abstract
Essence
Asian, Black, and Other race breast cancer patients with type 2 diabetes were less likely than White patients to receive GLP-1RAs.
Evidence
Retrospective TriNetX electronic health record cohort of 119,430 breast cancer patients with type 2 diabetes from 2005-2024, using propensity-matched race comparisons.
Caveat
The EHR cohort identifies treatment-use disparities but cannot determine the clinical, insurance, preference, or system-level causes.
Simplified
Key numbers
18,026 patients
Prescription Rate
15.1% of the overall study population were prescribed GLP-1RAs.
0.64
Lower Likelihood of Prescription
for Asian patients compared to White patients.
0.78
Lower Likelihood of Prescription
for Black patients compared to White patients.
GLP-1 Therapies